Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study

Shun-de, Wang; Ge, Chengguo; Zhang, Junyong

doi:10.3390/jcdd9080255

Cited by 4 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we were unable to eliminate all potential confounding variables completely, we did our best to validate the study results. Similar to earlier reports, [ 18 , 29 ] our investigation highlights a noteworthy decline in CVM susceptibility among cancer survivors who underwent surgery compared to their nonsurgical counterparts. Our results provide strong evidence indicating a link between CVM risk and tumor resection, further reinforcing the conclusion that resecting the primary tumor reduces the risk of CVM in cancer survivors.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Competing risk analysis of cardiovascular-specific mortality in typical carcinoid neoplasms of the lung: A SEER database analysis

Xing,

Wu,

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

Cardiovascular mortality (CVM) is a growing concern for cancer survivors. This study aimed to investigate the mortality patterns of individuals with typical carcinoid (TC) tumors, identify independent predictors of CVM, and compare these risk variables with those associated with TC deaths. The Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2019 was utilized for obtaining data on patients with TC. Standardized mortality rates were employed to evaluate the risk of CVM while multivariate competing risk models were used to determine the association between patient characteristics and the probability of CVM or TC-related deaths. Our findings show that TC patients had an increased risk of CVM, with an standardized mortality rates of 1.12 (95% CI:1.01–1.25). Furthermore, we discovered that age at diagnosis, marital status, year of diagnosis, SEER stage, site, year of diagnosis, surgery, radiotherapy, and chemotherapy all contributed independently to the risk of CVM in patients with TC, whereas age at diagnosis, sex, race, SEER stage, site, year of diagnosis, surgery, radiotherapy, and chemotherapy all contributed significantly to TC mortality. Compared to the general population in the United States, patients with TC are significantly more likely to acquire CVM. Timely introduction of cardioprotective treatments is critical for preventing CVM in patients with TC.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Competing risk analysis of cardiovascular-specific mortality in typical carcinoid neoplasms of the lung: A SEER database analysis

Xing,

Wu,

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…This is consistent with recent studies reporting increased CVD risk in bladder cancer, osteosarcoma, gallbladder cancer, colorectal cancer, and lymphoma. [ 25 , 30 , 46 – 48 ] Although the SMR was lowest in the elderly group, it was still higher 7 th an in the general elderly population. The reason for the higher SMR in the elderly group may be attributed to their poorer health, reduced immunity, and increased prevalence of comorbidities, including infections.…”

Section: Discussionmentioning

confidence: 93%

“…This trend may be attributed to the current advancements in treatment strategies for HCC patients, as well as the improved treatment and emergency measures for CVDs, as previously reported in the literature. [27–30] Additionally, our study identified age, tumor differentiation, tumor size, surgical status, and SEER stage as independent predictors of CVD in patients with HCC. These findings suggest that cardiovascular disease staging of HCC patients should be done in advance in the treatment and care of HCC patients in order to develop a rational therapeutic regimen thereby reducing the risk of cardiovascular mortality and improving the quality of life.…”

Section: Discussionmentioning

confidence: 99%

Analysis of competing risks of cardiovascular death in patients with hepatocellular carcinoma: A population-based study

Cao,

Wang,

Yan

et al. 2023

Medicine

View full text Add to dashboard Cite

Clinical data has shown that cardiovascular diseases (CVDs) have emerged as a prominent cause of mortality in individuals with hepatocellular carcinoma (HCC). This research aimed to reveal the comorbid effects of CVDs in patients with HCC. The cardiovascular mortality of patients diagnosed with HCC between 2000 and 2014 was compared to that of the general US population. Standardized mortality ratios were calculated to quantify the relative risk of cardiovascular mortality in HCC patients. The cumulative incidence of cardiovascular death (CVD) was estimated using Fine-Gray testing, and independent risk factors for CVD were determined using competing risk models. The results were analyzed using the Kaplan–Meier analysis. The overall SMR for CVD in HCC patients was 11.15 (95% CI: 10.99–11.32). The risk of CVD was significantly higher in patients aged < 55 years (SMR: 56.19 [95% CI: 54.97–57.44]) compared to those aged ≥ 75 years (SMR: 1.86 [95% CI: 1.75–1.97]). This study suggests that patients with HCC are at significant risk of developing CVD. Competing risk analyses indicated that age, grade, tumor size, surveillance, epidemiology, and end results stage, and surgical status were independent risk factors for CVD in patients with HCC. Therefore, patients with HCC require enhanced preventive screening and management of CVDs during and after treatment to improve patient survival.

show abstract

“…Bladder cancer as one of the most common malignancies in urology, patients are often more concerned about BC-related mortality. However, due to continuous medical advances and developments, the overall survival of BC patients has been effectively improved(Richters et al 2020 ; Lenis et al 2020 ; Marrie et al 2021 ), leading to the prominence of deaths from non-cancer diseases (Wang et al 2022a ).…”

Section: Discussionmentioning

confidence: 99%

High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid

Shun-de

2023

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose The objective of this study was to investigate non-cancer causes of death and associated risk factors after bladder cancer (BC) diagnosis. Methods Eligible BC patients were obtained from the SEER database. SEER*Stat software 8.3.9.2 was used to calculate the standardized mortality ratios (SMRs). The proportions of different non-cancer cause of death were calculated and analyzed in different follow-up periods. Multivariate competing risk model was used to analyze the risk factors for death of BC and non-cancer diseases. Results In total, 240,954 BC patients were included and 106,092 patients experienced death, with 37,205 (35.07%), 13,208 (12.45%) and 55,679 (52.48%) patients experienced BC, other cancer and non-cancer disease-related deaths, respectively. Overall SMR for BC patients who died from non-cancer diseases was 2.42 (95% CI [2.40–2.44]). Cardiovascular diseases were the most common non-cancer cause of death, followed by respiratory diseases, diabetes mellitus, and infectious diseases. Multivariate competing risk analysis identified the following high-risk factors for non-cancer mortality: age > 60 years, male, whites, in situ stage, pathological type of transitional cell carcinoma, not receiving treatment (including surgery, chemotherapy, or radiation), and widowed. Conclusions Cardiovascular diseases are the leading non-cancer cause of death in BC patients, followed by respiratory disease, diabetes mellitus and infectious diseases. Physicians should pay attention to the risk of death from these non-cancer diseases. Also, physicians should encourage patients to engage in more proactive self-surveillance and follow up.

show abstract

Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study

Cited by 4 publications

References 45 publications

Competing risk analysis of cardiovascular-specific mortality in typical carcinoid neoplasms of the lung: A SEER database analysis

Competing risk analysis of cardiovascular-specific mortality in typical carcinoid neoplasms of the lung: A SEER database analysis

Analysis of competing risks of cardiovascular death in patients with hepatocellular carcinoma: A population-based study

High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid

Contact Info

Product

Resources

About